1999 Presentations

2004 Presentations

2006 Presentations

2004 Workshop Presentations

Session 1: Model Qualification

• Fiedler-Kelly: Introduction to Workshop: Session I Content and Terms
• Gastonguay: Brief Overview of Model Qualification and Validation Methodologies
• Case Study 1: PopPK Analysis of a High-Dose Antineoplastic for Bone Marrow Transplant in Adults and Children
• Case Study 2: PopPK Analysis of an Intravenous Dose Ranging Study Evaluating an Antineoplastic Agent in Adults and Children
• Case Study 3: Drug X PK-PD Modeling/Simulation
• Case Study 4: Model Qualifications in Industrial Applications
• Duffull: Selecting The Right Model Across Modeling Platforms � A Pop PK/PD Perspective

Session 2: Software Validation

• Mould: Introduction to Workshop: Session II Content and Terms
• Gobburu: Population Analysis Software Validation: Good Practices
• Fiedler-Kelly: Example Documentation of Population Software Validation Efforts

2004 Scientific Meeting Presentations

• Booth: "Population Pharmacokinetic Modeling and Simulation-Derived Dosing of Intravenous Busulfan in Pediatric Patients"
• Gopalakrishnon: "A Pharmacokinetic-Pharmacodynamic Model for Insulin to Guide Optimal Drug Delivery"
• Jadhav: "Mixed Effects Model Qualification Using Predictive Check"
• Duan: "Population Pharmacokinetics in Assessing Drug-Drug Interactions: Consideration During Regulatory Review"
• Guzy: "Application of the Monte Carlo Parametric Expectation Maximization (MCPEM) Algorithm for Analyzing Population Pharmacokinetic/Pharmacodynamic (PK/PD) Data"
• Li: "Impact of Mis-specified Residual Model on Parameter Estimates in Population Pharmacokinetic Analysis"
• Nedelman: "Diagnostics for Confounding in a PK/PD Model"
• Madabushi: "Mixed Effects Modeling of Sparse Data: A Comparison of Three Software Packages"
• Tornoe: "Stochastic Differential Equations in NONMEM: A Diagnostic Tool for Pinpointing Model Deficiencies"
• Lee: "Population Pharmacokinetics of Troxacitabine"